Mikkel Rostock-Jensen
In recent years, Mikkel's capital markets experience has focused on IPOs and secondary capital issues (rights issues, accelerated book-buildings and private investment in public equity). Mikkel has also been involved in and has experience with public M&A transactions (takeover bids/takeovers) and general capital markets advice.
Mikkel's M&A transaction experience includes all types of transactions (acquisitions, sales, investments (including venture investments), joint ventures, partnership/licensing, restructurings, etc.) often on behalf of listed and large cap companies and in connection with complex processes.
Mikkel has extensive experience with the biotech sector.
Mikkel has a Master’s degree in Law from the University of Copenhagen.
Almost all the matters in which Mikkel is involved require a multi-disciplinary team approach and project leadership. He and the team are continuously sought by clients for their ability to provide a clear set of priorities, clear communication, and a deep commercial understanding of clients' needs.
Selected cases
- Advised the Danish State on acquisition of 59.4% stake in Copenhagen Airport
- Advised Zealand Pharma on license of CT-388 (obesity) to F Hoffmann-La Roche
- Advised Gubra on license of GUB014295 (obesity) to AbbVie
- Advised the Danish State on reorganisation of and investment in SAS
- Advised Zealand Pharma on repeated private placements
- Advised Gubra on IPO on Nasdaq Copenhagen
- Advised the Danish State in connection with the IPO of Dong Energy (now Ørsted)
- Advised ISS on IPO on Nasdaq Copenhagen
- Advised Union Therapeutics on repeated investments
- Advised Macquarie on public takeover offer to TDC's shareholders
- Advised Zealand Pharma on IPO and dual‐listing on NASDAQ Global Select
- Advised Shark Solution on investment from AXA
- Advised underwriters on IPO of Nets
- Advised underwriters on IPO of Scandinavian Tobacco Group
- Advised Ørsted on private placement of new shares to Goldman Sachs, etc.
- Advised Veloxis Pharmaceuticals on public takeover by Asahi Kasei
- Advised Danske Bank on Arbejdernes Landsbank right issue
- Advised HBM Healthcare Investments on investment in IO Biotech
- Advised ABGSC on two private placements in GreenMobility
- Advised underwriters in connection with rights issue in Bavarian Nordic
- Advised underwriters on US IPO and establishment of ATP program of Orphazyme in the US
- Advised underwriters on rights issue in Green Hydrogen Systems
